14 peer-reviewed studies · Evidence score: 7/10
Perng CH et al. • Psychopharmacology (2018)
The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
Deutschenbaur L et al. • Progress in neuro-psychopharmacology & biological psychiatry (2016)
Based on glutamatergic signaling, a number of therapeutic drugs might gain interest in the future.
O'Neill MJ et al. • Current drug targets (2007)
The present review summarises studies into the effects of AMPA receptor potentiators (with a focus on the biarylpropylsulfonamides) in rodent models of depression and Parkinson's disease.
Arai AC et al. • Current drug targets (2007)
Type II drugs like CX516 in particular appear to be inherently safe since their ability to prolong responses is kinetically limited.
Francotte P et al. • Recent patents on CNS drug discovery (2006)
The major chemical families developed as AMPA potentiators are aniracetam derivatives, cyclothiazide derivatives and biarylpropylsulfonamides derivatives.
Malykh AG, Sadaie MR • Drugs (2010)
The racetam family shows promising cognitive-enhancing effects, though clinical evidence quality varies across compounds.
Zhong J et al. • Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007)
Shenwu gelatin capsule has certain effects on mild cognitive impairment.
Li SK et al. • Zhongguo zhen jiu = Chinese acupuncture & moxibustion (2014)
The scalp acupuncture combined with auricular point sticking could improve the clinical symptoms and cognitive behavior ability in patients with vascular dementia, which has superior total efficacy to body acupuncture and western medication aniracetam tablets.
Li H et al. • Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine (2008)
Huannao Yicong capsule has better therapeutic effect than aniracetam capsule in treating senile mild cognitive impairment.
Guo RZ et al. • Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine (2010)
For treatment of MCI, HWD shows effects in improving patients' symptoms, cognition capacity and elevating serum Ach content better than that of Aniracetam; and with effects for raising SOD activity and reducing MDA level similar to those of Aniracetam.
Tian Y et al. • Arzneimittel-Forschung (2008)
Therefore, the aniracetam test formulation can be regarded as bioequivalent to the aniracetam reference formulation.
Koliaki CC et al. • CNS neuroscience & therapeutics (2012)
Our findings indicate that aniracetam (a nootropic compound with glutamatergic activity and neuroprotective potential) is a promising option for patients with cognitive deficit of mild severity.
Krampfl K et al. • European journal of pharmacology (2005)
The pharmacological effect described resembles in part that of compounds like cyclothiazide and aniracetam which are known to interact with channel desensitization.
Elston TW, Bhatt A, Bhatt DL • BMC Neuroscience (2020)
Aniracetam reversed LPS-induced cognitive deficits and reduced neuroinflammatory markers in a mouse model.